255 related articles for article (PubMed ID: 14981127)
1. Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis.
Ohazama A; Courtney JM; Sharpe PT
J Dent Res; 2004 Mar; 83(3):241-4. PubMed ID: 14981127
[TBL] [Abstract][Full Text] [Related]
2. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2004 Jan; 33(1):46-52. PubMed ID: 14675140
[TBL] [Abstract][Full Text] [Related]
3. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
Suzuki T; Suda N; Ohyama K
J Bone Miner Metab; 2004; 22(3):185-91. PubMed ID: 15108059
[TBL] [Abstract][Full Text] [Related]
4. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
5. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
[TBL] [Abstract][Full Text] [Related]
6. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
8. Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement.
Kanzaki H; Chiba M; Takahashi I; Haruyama N; Nishimura M; Mitani H
J Dent Res; 2004 Dec; 83(12):920-5. PubMed ID: 15557398
[TBL] [Abstract][Full Text] [Related]
9. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
Tian QX; Huang GY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):418-22. PubMed ID: 15379268
[TBL] [Abstract][Full Text] [Related]
10. Chronology and regulation of gene expression of RANKL in the rat dental follicle.
Liu D; Yao S; Pan F; Wise GE
Eur J Oral Sci; 2005 Oct; 113(5):404-9. PubMed ID: 16202028
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
13. The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts.
Boabaid F; Berry JE; Koh AJ; Somerman MJ; McCcauley LK
J Periodontol; 2004 Sep; 75(9):1247-54. PubMed ID: 15515341
[TBL] [Abstract][Full Text] [Related]
14. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
[TBL] [Abstract][Full Text] [Related]
15. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice.
Maruyama K; Takada Y; Ray N; Kishimoto Y; Penninger JM; Yasuda H; Matsuo K
J Immunol; 2006 Sep; 177(6):3799-805. PubMed ID: 16951341
[TBL] [Abstract][Full Text] [Related]
16. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
Kostenuik PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint.
Carda C; Silvestrini G; Gomez de Ferraris ME; Peydró A; Bonucci E
Tissue Cell; 2005 Jun; 37(3):247-55. PubMed ID: 15899507
[TBL] [Abstract][Full Text] [Related]
19. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
Hofbauer LC
Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
